BRIEF published on 12/09/2025 at 14:55, 8 months 3 days ago Teva Pharmaceuticals submits an application for authorization for Olanzapine LAI FDA Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI
BRIEF published on 12/09/2025 at 14:55, 8 months 3 days ago Medincell and Teva Submit FDA Application for New Injectable Treatment Schizophrenia Treatment Medincell FDA Submission Teva Pharmaceuticals Olanzapine LAI
PRESS RELEASE published on 12/09/2025 at 14:50, 8 months 3 days ago Inside Information / Other news releases Teva Pharmaceuticals submits NDA to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for Once-Monthly Schizophrenia Treatment. Medincell focuses on long-acting injectable treatments across therapeutic areas Schizophrenia Medincell Olanzapine NDA Teva Pharmaceuticals
BRIEF published on 11/11/2025 at 08:05, 9 months 1 day ago Medincell Expands Dr Grace Kim's Role to Boost US Capital Growth Biotechnology Medincell Pharmaceutical Strategy Dr Grace Kim US Capital Growth
PRESS RELEASE published on 11/11/2025 at 08:00, 9 months 1 day ago Inside Information / Other news releases Medincell appoints Dr. Grace Kim as Chief Strategy Officer, U.S. Finance to lead U.S. capital growth strategy. Medincell pioneers long-acting injectable therapies Medincell Dr. Grace Kim Long-acting Injectable Therapies U.S. Capital Growth Clinical-stage Pharmaceutical Company
BRIEF published on 11/05/2025 at 13:51, 9 months 7 days ago Continued growth for Medincell and new prospects with Olanzapine LAI Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 9 months 7 days ago Inside Information / Other news releases Medincell's partner Teva plans US NDA submission for Olanzapine LAI in Q4 2025, while UZEDY® achieves continued growth in sales in Q3 2025 Medincell Teva Pharmaceuticals Olanzapine LAI US NDA Submission UZEDY Sales Growth
BRIEF published on 10/10/2025 at 22:16, 10 months 1 day ago FDA Approves UZEDY for Bipolar I Disorder in Adults FDA Approval Mental Health Treatment UZEDY Bipolar I Disorder Risperidone
PRESS RELEASE published on 10/10/2025 at 22:11, 10 months 1 day ago Inside Information / Other news releases FDA approves UZEDY as extended-release injectable suspension for bipolar I disorder treatment in adults. Teva and Medincell collaborate on this significant advancement in neuroscience FDA Medincell Teva UZEDY Bipolar I Disorder
BRIEF published on 09/17/2025 at 14:05, 10 months 25 days ago Medincell and Teva Present Phase 3 Olanzapine LAI Data Phase 3 Trial Schizophrenia Treatment Medincell Teva Olanzapine LAI
Published on 08/12/2026 at 15:00, 1 minute ago Karbon-X and Core Energy Sign Letter of Intent to Explore Commercial EV Charging Infrastructure in South America
Published on 08/12/2026 at 14:45, 16 minutes ago Lobe Sciences Ltd. Announces Non-Brokered Private Placement
Published on 08/12/2026 at 14:00, 1 hour 1 minute ago International Battery Metals Appoints Scott Colangelo to Board of Directors
Published on 08/12/2026 at 13:55, 1 hour 6 minutes ago Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study
Published on 08/12/2026 at 14:30, 31 minutes ago Iute Group Reports Unaudited 6M 2026 Results on 27 August 2026 – Invitation to Earnings Webcast/Call on the Same Day
Published on 08/12/2026 at 14:10, 51 minutes ago Pudu Robotics Launches PUDU ET1, an AI-Native Compact Scrubber-Dryer Robot for Small Commercial Spaces
Published on 08/12/2026 at 13:58, 1 hour 3 minutes ago EQS-Adhoc: Vitruvia Medical AG: Half yearly results as per June 30,2026
Published on 08/12/2026 at 13:38, 1 hour 23 minutes ago Nebius reports second quarter 2026 financial results
Published on 08/10/2026 at 18:00, 1 day 21 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 11:53, 2 days 3 hours ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
Published on 08/10/2026 at 11:36, 2 days 3 hours ago GUILLEMOT CORPORATION| Weekly report share buyback from August 3 to August 7 2026
Published on 08/10/2026 at 09:22, 2 days 5 hours ago Number of shares and voting rights - July 2026 (In French only)
